BR122012009489B8 - processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso - Google Patents

processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso

Info

Publication number
BR122012009489B8
BR122012009489B8 BR122012009489A BR122012009489A BR122012009489B8 BR 122012009489 B8 BR122012009489 B8 BR 122012009489B8 BR 122012009489 A BR122012009489 A BR 122012009489A BR 122012009489 A BR122012009489 A BR 122012009489A BR 122012009489 B8 BR122012009489 B8 BR 122012009489B8
Authority
BR
Brazil
Prior art keywords
methyl
oxo
salt
dioxol
benzimidazol
Prior art date
Application number
BR122012009489A
Other languages
English (en)
Other versions
BR122012009489B1 (pt
Inventor
Kuroita Takanobu
Sakamoto Hiroki
Ojima Mami
Original Assignee
Darwin Prestacao De Servicos De Marketing Ltda
Takeda Pharmaceuticals Co
Takeda Pharmaceuticals Int Ag
Hypera S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122012009489(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Darwin Prestacao De Servicos De Marketing Ltda, Takeda Pharmaceuticals Co, Takeda Pharmaceuticals Int Ag, Hypera S A filed Critical Darwin Prestacao De Servicos De Marketing Ltda
Publication of BR122012009489B1 publication Critical patent/BR122012009489B1/pt
Publication of BR122012009489B8 publication Critical patent/BR122012009489B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

composto ou um sal do mesmo, processo para produzir um composto, medicamento, e, uso do composto. a presente invenção está relacionada a um composto representado pela fórmula (i) (i) onde r1 é um grupo representado pelas fórmulas ou onde r2, r3, r4, r5, r6, r7 e r8 são cada um independentemente um átomo de hidrogênio ou um c1-6 alquila, ou um sal do mesmo. o composto da presente invenção é útil como um agente para profilaxia ou para tratamento de doenças circulatórias tais como hipertensão e similares, e doenças metabólicas tais como diabetes e similares.
BR122012009489A 2004-02-25 2005-02-23 processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso BR122012009489B8 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2004-048928 2004-02-25
JP2004048928 2004-02-25
US11/031,057 US7157584B2 (en) 2004-02-25 2005-01-07 Benzimidazole derivative and use thereof
US11/031,057 2005-01-07
PCT/JP2005/003422 WO2005080384A2 (en) 2004-02-25 2005-02-23 Benzimidazole derivative and use as aii receptor antagonist
BRPI0507984A BRPI0507984B8 (pt) 2004-02-25 2005-02-23 composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamífero, para melhorar a resistência de insulina em um mamífero e para prevenir ou tratar doenças circulatórias em um mamífero, e, uso do composto

Publications (2)

Publication Number Publication Date
BR122012009489B1 BR122012009489B1 (pt) 2019-02-19
BR122012009489B8 true BR122012009489B8 (pt) 2023-03-21

Family

ID=34858222

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0507984A BRPI0507984B8 (pt) 2004-02-25 2005-02-23 composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamífero, para melhorar a resistência de insulina em um mamífero e para prevenir ou tratar doenças circulatórias em um mamífero, e, uso do composto
BR122012009489A BR122012009489B8 (pt) 2004-02-25 2005-02-23 processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0507984A BRPI0507984B8 (pt) 2004-02-25 2005-02-23 composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamífero, para melhorar a resistência de insulina em um mamífero e para prevenir ou tratar doenças circulatórias em um mamífero, e, uso do composto

Country Status (33)

Country Link
US (3) US7157584B2 (pt)
EP (3) EP1857457B1 (pt)
JP (2) JP4256852B2 (pt)
KR (1) KR101080029B1 (pt)
CN (2) CN101381366B (pt)
AR (2) AR047972A1 (pt)
AT (2) ATE440095T1 (pt)
AU (1) AU2005214271B8 (pt)
BR (2) BRPI0507984B8 (pt)
CA (1) CA2557538C (pt)
CY (5) CY1107008T1 (pt)
DE (3) DE602005002030T2 (pt)
DK (3) DK1718641T3 (pt)
ES (3) ES2388945T3 (pt)
HK (2) HK1098472A1 (pt)
HR (3) HRP20070510T3 (pt)
HU (1) HUS1200008I1 (pt)
IL (1) IL177533A (pt)
LU (1) LU91962I2 (pt)
MA (1) MA28478B1 (pt)
ME (2) ME01643B (pt)
MY (1) MY142807A (pt)
NL (1) NL300802I2 (pt)
NO (2) NO332344B1 (pt)
NZ (1) NZ549755A (pt)
PL (3) PL1857457T3 (pt)
PT (3) PT1718641E (pt)
RS (3) RS51137B (pt)
RU (2) RU2369608C2 (pt)
SI (3) SI1718641T1 (pt)
TW (1) TWI336702B (pt)
WO (1) WO2005080384A2 (pt)
ZA (1) ZA200607241B (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
WO2006066361A1 (en) 2004-12-24 2006-06-29 The University Of Queensland Method of treatment or prophylaxis
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
DE602006017183D1 (de) * 2005-03-30 2010-11-11 Takeda Pharmaceutical Benzimidazolderivat und anwendung davon
US20090012132A1 (en) * 2006-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Pharmaceutical Package
WO2007097452A1 (ja) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬用ブリスターパッケージ
NZ572046A (en) * 2006-03-20 2012-03-30 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis inflammatory pain
ATE552818T1 (de) * 2006-09-25 2012-04-15 Takeda Pharmaceutical Medizinische verpackung
BRPI0809522A2 (pt) * 2007-03-28 2014-10-14 Takeda Pharmaceutical Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.
JP2009062296A (ja) * 2007-09-05 2009-03-26 Fujifilm Corp カルボン酸エステル化合物の製造方法
ES2510866T3 (es) * 2008-03-13 2014-10-21 Daiichi Sankyo Company, Limited Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo
UY32017A (es) * 2008-07-31 2010-02-26 Takeda Pharmaceutical Composición farmacéutica sólida
UY32126A (es) * 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
US8410284B2 (en) * 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
WO2012090043A1 (en) 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Novel solid state forms of azilsartan medoxomil and preparation thereof
AU2012208863B2 (en) 2011-01-20 2016-07-28 Jiangsu Hansoh Medicine Institute Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof
JP2014505097A (ja) 2011-02-08 2014-02-27 ジュビラント ライフ サイエンセズ リミテッド アジルサルタンメドキソミルの改良製造方法
CN102138899B (zh) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 阿齐沙坦酯脂质体固体制剂
CA2832938C (en) 2011-04-13 2019-09-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
CN102827153B (zh) * 2011-06-14 2016-10-05 江苏豪森药业集团有限公司 阿齐沙坦的晶型及其制备方法
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2013042067A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of potassium salt of azilsartan medoxomil
WO2013042066A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil
AP2014007766A0 (en) 2011-12-15 2014-07-31 Takeda Pharmaceuticals Usa Inc Combination os azilsartan and chlorthlidone for treating hypertension black patients
WO2013088384A2 (en) 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
US9403811B2 (en) 2012-01-14 2016-08-02 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan medoxomil potassium and preparation and uses thereof
IN2014DN06964A (pt) * 2012-02-02 2015-04-10 Ranbaxy Lab Ltd
WO2013124748A1 (en) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Novel polymorphs of azilsartan medoxomil potassium
CZ2012274A3 (cs) * 2012-04-19 2013-10-30 Zentiva, K.S. Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (en) * 2012-06-11 2013-12-19 Msn Laboratories Limited Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts
CA2884248A1 (en) * 2012-07-09 2014-01-16 Hetero Research Foundation Novel polymorphs of azilsartan
WO2014020381A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Novel crystalline form of azilsartan medoxomil potassium
US9624207B2 (en) 2012-08-27 2017-04-18 Hetero Research Foundation Polymorphs of azilsartan medoxomil
CZ305318B6 (cs) * 2012-09-26 2015-07-29 Zentiva, K.S. Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
WO2014049512A2 (en) 2012-09-26 2014-04-03 Lupin Limited Novel process for preparation of azilsartan medoxomil
CN105237527B (zh) * 2012-09-28 2018-03-06 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
US9738817B2 (en) * 2012-10-09 2017-08-22 Avery Dennison Corporation Adhesives and related methods
CN103910720A (zh) * 2013-01-07 2014-07-09 广东东阳光药业有限公司 阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535005C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
RU2535004C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
CN105949182B (zh) * 2013-10-12 2019-03-19 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104812752B (zh) * 2013-10-12 2016-09-28 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104774196B (zh) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN104774197B (zh) * 2014-01-09 2017-11-17 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
CN104016974A (zh) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) * 2014-11-21 2016-06-01 重庆朗天制药有限公司 一种阿奇沙坦酯钾盐及其中间体新的制备方法
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
WO2016145622A1 (zh) 2015-03-18 2016-09-22 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
CN106032378B (zh) * 2015-03-20 2019-10-25 武汉启瑞药业有限公司 新型arb化合物及其用途
CN104803998B (zh) * 2015-03-26 2017-08-25 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
EP3328381A1 (en) * 2015-07-29 2018-06-06 Takeda GmbH Pde4 inhibitor for the treatment of diabetic nephropathy
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6856365B2 (ja) * 2016-11-30 2021-04-07 株式会社トクヤマ アジルサルタンの製造方法
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法
CN105628824B (zh) * 2016-03-06 2017-10-17 江苏正大清江制药有限公司 一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN112110909A (zh) * 2016-05-20 2020-12-22 武汉朗来科技发展有限公司 化合物及其制备方法、组合物和应用
CN105770876B (zh) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 乌司他丁在制备治疗慢性前列腺炎药物中的用途
CN107602546B (zh) * 2016-07-11 2022-04-22 武汉朗来科技发展有限公司 化合物的晶型及其制备方法、组合物和应用
RU2623082C1 (ru) * 2016-07-11 2017-06-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ коррекции артериальной ригидности у больных ревматоидным артритом
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法
US11096928B2 (en) * 2016-10-08 2021-08-24 Wuhan Ll Science And Technology Development Co., Ltd. Pharmaceutical composition
WO2019130277A1 (en) 2017-12-30 2019-07-04 Lupin Limited Pharmaceutical formulations of azilsartan medoxomil
CN110237072B (zh) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 药物组合物的制备方法
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
CN117542473A (zh) 2018-06-14 2024-02-09 阿斯利康(英国)有限公司 用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
JP7470647B2 (ja) * 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド ジヒドロピリジン型カルシウムチャネル遮断薬医薬組成物を用いて血圧を低下させるための方法
KR20200057662A (ko) 2018-11-16 2020-05-26 엠에프씨 주식회사 아질사르탄 유도체 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물
JPWO2020166710A1 (ja) * 2019-02-15 2021-12-16 国立大学法人東北大学 １，３−ジオキソラン誘導体
KR102220011B1 (ko) 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN113912580B (zh) * 2021-11-03 2023-06-02 瑞孚信江苏药业股份有限公司 一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
KR20240039252A (ko) 2022-09-19 2024-03-26 대봉엘에스 주식회사 안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62290071A (ja) 1986-06-09 1987-12-16 Matsushita Electric Ind Co Ltd 有機電解質二次電池
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2117668C1 (ru) * 1991-10-23 1998-08-20 Эйсаи Ко., Лтд. Производное оксазолидона или его фармакологически приемлемые соли, фармацевтическая композиция, способ лечения
US5310929A (en) 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
JP2787539B2 (ja) * 1993-02-26 1998-08-20 松森　　昭 ウイルス性疾患の予防または治療剤
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) 1995-04-03 1997-03-11 Bristol-Myers Squibb Company Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
US6974806B2 (en) 2000-07-13 2005-12-13 Takeda Pharmaceutical Company Limited Lipid-rich plaque inhibitors
US20050032854A1 (en) 2001-12-03 2005-02-10 Kiminori Kawahara Insulin resistance improving agents
US20050020634A1 (en) 2002-01-11 2005-01-27 Terashita Zen-Ichi Coumarin derivatives, process for their production and use thereof
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
US6972258B2 (en) * 2003-08-04 2005-12-06 Taiwan Semiconductor Manufacturing Co., Ltd. Method for selectively controlling damascene CD bias
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4364171B2 (ja) 2005-07-15 2009-11-11 本田技研工業株式会社 自動車用ドアチェッカ
UA58542U (ru) * 2010-12-16 2011-04-11 Леонид Борисович Борейко Способ фиксирования эвакуационной машины во время вытягивания застрявшей тяжелой машины

Also Published As

Publication number Publication date
NO2012017I2 (no) 2012-11-09
DK1857457T3 (da) 2009-12-21
SI1857457T1 (sl) 2010-01-29
PL1718641T3 (pl) 2008-01-31
WO2005080384A3 (en) 2006-09-28
DE122012000018I1 (de) 2012-06-06
EP1857457A3 (en) 2007-12-05
ES2388945T3 (es) 2012-10-22
HK1098472A1 (en) 2007-07-20
HRP20090593T1 (hr) 2010-03-31
DE602005002030T2 (de) 2008-05-08
ES2331209T3 (es) 2009-12-23
EP1718641B1 (en) 2007-08-15
ME01643B (me) 2010-05-07
IL177533A0 (en) 2006-12-10
BRPI0507984B8 (pt) 2023-03-21
AU2005214271B2 (en) 2011-02-24
TW200530227A (en) 2005-09-16
RU2009115498A (ru) 2010-10-27
CY1113084T1 (el) 2016-04-13
NO332344B1 (no) 2012-09-03
CN101381366B (zh) 2011-06-15
CY2012015I2 (el) 2016-12-14
AU2005214271A2 (en) 2005-09-01
ATE370136T1 (de) 2007-09-15
NZ549755A (en) 2009-04-30
TWI336702B (en) 2011-02-01
ES2293552T3 (es) 2008-03-16
AR047972A1 (es) 2006-03-15
US7157584B2 (en) 2007-01-02
KR20070020411A (ko) 2007-02-21
MY142807A (en) 2011-01-14
DE602005002030D1 (de) 2007-09-27
NO20064251L (no) 2006-11-22
HRP20120667T2 (hr) 2012-11-30
EP2119715B1 (en) 2012-05-30
EP1857457B1 (en) 2009-08-19
HRP20070510T3 (en) 2007-12-31
RS51137B (sr) 2010-10-31
US7572920B2 (en) 2009-08-11
PT1718641E (pt) 2007-11-15
BRPI0507984A (pt) 2007-07-24
CY1109610T1 (el) 2014-08-13
HUS1200008I1 (hu) 2017-06-28
PL1857457T3 (pl) 2009-12-31
DE602005016162D1 (de) 2009-10-01
CY2012015I1 (el) 2016-12-14
US20090270464A1 (en) 2009-10-29
CY2012016I1 (el) 2016-12-14
EP1857457A2 (en) 2007-11-21
RS50537B (sr) 2010-05-07
ME01089B (me) 2013-03-20
DK2119715T3 (da) 2012-09-10
DK1718641T3 (da) 2007-12-17
ATE440095T1 (de) 2009-09-15
HRP20120667T1 (en) 2012-09-30
CA2557538A1 (en) 2005-09-01
RU2501798C2 (ru) 2013-12-20
PT1857457E (pt) 2009-09-23
IL177533A (en) 2010-12-30
KR101080029B1 (ko) 2011-11-04
ZA200607241B (en) 2008-04-30
EP2119715A1 (en) 2009-11-18
WO2005080384A2 (en) 2005-09-01
JP4256852B2 (ja) 2009-04-22
US20060281795A1 (en) 2006-12-14
NO2012017I1 (no) 2012-11-26
CN1946717A (zh) 2007-04-11
NL300802I2 (pt) 2016-05-18
CA2557538C (en) 2010-08-17
LU91962I2 (fr) 2012-05-21
BRPI0507984B1 (pt) 2018-07-03
CY2012016I2 (el) 2016-12-14
PL2119715T3 (pl) 2012-10-31
RU2006133898A (ru) 2008-03-27
CY1107008T1 (el) 2012-09-26
SI1718641T1 (sl) 2007-12-31
AU2005214271A1 (en) 2005-09-01
RU2369608C2 (ru) 2009-10-10
AU2005214271B8 (en) 2011-03-03
BR122012009489B1 (pt) 2019-02-19
WO2005080384A9 (en) 2006-11-30
HK1115118A1 (en) 2008-11-21
AR094588A2 (es) 2015-08-12
US20050187269A1 (en) 2005-08-25
SI2119715T1 (sl) 2012-10-30
PT2119715E (pt) 2012-09-03
MA28478B1 (fr) 2007-03-01
CN100503605C (zh) 2009-06-24
EP1718641A2 (en) 2006-11-08
JP2005272451A (ja) 2005-10-06
RS52376B (en) 2012-12-31
CN101381366A (zh) 2009-03-11
JP2009137974A (ja) 2009-06-25
US7875637B2 (en) 2011-01-25

Similar Documents

Publication Publication Date Title
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
MY173930A (en) Crystalline solvates and complexes of (is)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
ATE515505T1 (de) Heterocyclische fxr-bindende verbindungen
NO20055688L (no) Organiske forbindelser
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
NZ602754A (en) Substituted 1,3-benzothiazepines useful in treating metabolic disorders
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
SE0104334D0 (sv) Therapeutic agents
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
ATE484502T1 (de) Neue verbindungen
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
SE0201937D0 (sv) Therapeutic agents
ATE338042T1 (de) Hetero-bicyclische crf antagonisten
TW200833697A (en) Spiro-piperidine derivatives
ATE432262T1 (de) Pyrazolphenylderivate als ppar-aktivatoren
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
BRPI0707203B8 (pt) compostos derivados de indoloquinoxalina úteis para o tratamento de infecções virais, método para preparar os compostos, e, composição farmacêutica
BRPI0417639A (pt) compostos, processo para preparar os mesmos, agente, semente, e, processo para combater fungos nocivos fitopatogênicos
TH62190A (th) สารประกอบอินทรีย์
TH84547B (th) สารรักษาโรค
TH107389A (th) อนุพันธ์แอลคิลไธแอโซลคาร์บาเมท การเตรียมสารเหล่านี้และการใช้สารเหล่านี้ในการรักษาโรค

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B25C Requirement related to requested transfer of rights

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870200120251 DE 24/09/2020, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICALS INTERNATIONAL AG (CH)

B25A Requested transfer of rights approved

Owner name: DARWIN PRESTACAO DE SERVICOS DE MARKETING LTDA. (BR/SP)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/02/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B25A Requested transfer of rights approved

Owner name: HYPERA S.A. (BR/SP)